CSIR Central

Comparative antirelapse efficacy of CDRI compound 80/53 (Bulaquine) vs primaquine in double blind clinical trail

IR@CDRI: CSIR-Central Drug Research Institute, Lucknow

View Archive Info
 
 
Field Value
 
Creator Valecha, Neena
Adak, T
Bagga, A K
Asthana, O P
Srivastava, J S
Joshi, Hema
Sharma, V P
 
Date 2009-09-08T09:02:25Z
2009-09-08T09:02:25Z
2001
 
Identifier Current Science-2001, 80, 561-563
http://hdl.handle.net/123456789/508
 
Description One year follow-up of malaria patients was under-taken to minitor the antirelapse efficacy of CDRI compound 80/53 (Bulaquine).a total of 697 patients of plasmodium vivax malaria were included in three arm double blind randomized study comparing CDRI 80/53 with placebo and primaquine. Drugs were givan once a day for 5 days and the dose for CDRI 80/53 and primaquine was 25 mg and 15 mg, respectively. Thirty-four patients were lost to follow-up and 663 patients completed one year trail. Two hundred and fourteen patients came back with second episode during the one-year followup period. A detailed analysis revealed that the relapse rate during non-transmission period with placebo in 16 (10.6%) patients was higher than both in primaquine (3.0%) and CDRI 80/53 (4.9%) groups.
 
Format 33746 bytes
application/pdf
 
Language en
 
Title Comparative antirelapse efficacy of CDRI compound 80/53 (Bulaquine) vs primaquine in double blind clinical trail
 
Type Article